130 related articles for article (PubMed ID: 22782858)
21. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
22. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
23. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
[TBL] [Abstract][Full Text] [Related]
24. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Rofstad EK; Halsør EF
Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
[TBL] [Abstract][Full Text] [Related]
26. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
28. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP
Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
[TBL] [Abstract][Full Text] [Related]
29. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
30. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Nicoli S; Ribatti D; Cotelli F; Presta M
Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
[TBL] [Abstract][Full Text] [Related]
31. γ-Tocotrienol inhibits angiogenesis of human umbilical vein endothelial cell induced by cancer cell.
Li Y; Sun WG; Liu HK; Qi GY; Wang Q; Sun XR; Chen BQ; Liu JR
J Nutr Biochem; 2011 Dec; 22(12):1127-36. PubMed ID: 21292465
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
Cao Y
Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Dang DT; Chun SY; Burkitt K; Abe M; Chen S; Havre P; Mabjeesh NJ; Heath EI; Vogelzang NJ; Cruz-Correa M; Blayney DW; Ensminger WD; St Croix B; Dang NH; Dang LH
Cancer Res; 2008 Mar; 68(6):1872-80. PubMed ID: 18339868
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
35. Tumor-initiating cells and tumor vascularization.
Zhang LZ; Zhang CQ; Yan ZY; Yang QC; Jiang Y; Zeng BF
Pediatr Blood Cancer; 2011 Mar; 56(3):335-40. PubMed ID: 21225908
[TBL] [Abstract][Full Text] [Related]
36. Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy.
Benayoun L; Schaffer M; Bril R; Gingis-Velitski S; Segal E; Nevelsky A; Satchi-Fainaro R; Shaked Y
Cancer Biol Ther; 2013 Jan; 14(1):64-74. PubMed ID: 23114641
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic effects of marine sponge derived compounds on cancer.
Senthilkumar K; Venkatesan J; Manivasagan P; Kim SK
Environ Toxicol Pharmacol; 2013 Nov; 36(3):1097-108. PubMed ID: 24148290
[TBL] [Abstract][Full Text] [Related]
38. Current insights into the association of Nestin with tumor angiogenesis.
Onisim A; Achimas-Cadariu A; Vlad C; Kubelac P; Achimas-Cadariu P
J BUON; 2015; 20(3):699-706. PubMed ID: 26214620
[TBL] [Abstract][Full Text] [Related]
39. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
40. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.
Eyler CE; Rich JN
J Clin Oncol; 2008 Jun; 26(17):2839-45. PubMed ID: 18539962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
